
Erasca Faces Class Action Over Alleged Misleading Oncology Data
A shareholder class action lawsuit has been filed against Erasca, Inc. following revelations that the oncology firm allegedly misrepresented the preclinical data of its drug candidate, ERAS-0015. Investors who acquired securities between January 14, 2025, and April 26, 2026, are now being represented by the law firm Robbins LLP.


























